PharmaCyte Biotech Inc (PMCB)

[DragonBear]

Cancer Licensing Agreement???

The interesting question is why PMCB? One has 4 research articles dating back to: 1999, 2001, and 2 in 2003. Yet not one major Pharma company was interested in obtaining an exclusive license. Seems the major Pharma companies judged low dose ifosfamide by any administrative method wasn't worth pursuing. The result for Austrianova is they couldn't attract funding.

PMCB in the last 10Q had $2.3M in cash. Yeah, that would probably be enuff to cover a Phase I trial - if they ever get an IND. Then again, they claimed they lost -$1M in operating expenses for that quarter. With the insiders taking a $415K cut in "compensation", and another $254K in salary. Waggoner&Crabtree aren't going to be in any soup lines with the $350K combined salaries. Another couple of Qs, and the cash will be gone. Time for some more share dilution?

If cell-in-a-box (cat-in-the-hat) was worth anything, PMCB would've attracted major private equity funding, and issued an IPO on the NAS years ago. Instead it sits as the usual Microcrap biotech scam in the OTC market.